Our Services
Praneet Valodia Consulting has been involved in many areas of consulting to the private and public sectors with the goal of delivering affordable and quality healthcare. We are committed to the transfer of skills in all the projects that we are involved with.
Healthcare Strategy / medicines policy
Praneet has been involved in healthcare strategy since 1998 as a consultant to medical schemes (e.g. Pro Sano), 3 large managed healthcare companies, 15 multinational pharmaceutical companies, hospital groups and numerous other healthcare companies. In his current role he provides strategic advice and independent views on the South African healthcare landscape to local and international role players. He has been actively involved in advising on medicines policy. Currently, he is focusing on the delivery of affordable and quality healthcare in South Africa.
Pharmacoeconomics / market access
Praneet is involved with health technology assessment particularly for innovator medicines and in developing pharmacoeconomic models to assist with re-imbursement strategies and improving market access. He has presented at over 30 conferences/workshops on pharmacoeconomics locally and internationally. He was a member of the Pricing Committee (appointed by Ministers of Health from 2005 to 2016) and chairman of that committee’s Pharmacoeconomics Task Team. He currently supervises postgraduate students in pharmacoeconomics / health economics.
IT systems development
A key focus of his work is to develop IT systems that use health and artificial intelligence. He has developed automated systems to improve operational efficiency. In this respect, he has served as head of product development involved in developing medicines, hospital, disease management, PMB, PBM, etc. systems. His current work involves developing IT systems that measure clinical control in line with accepted clinical guidelines. These systems use decisions trees for clinical decision-making.
Managed healthcare and medical scheme management
​
Praneet has been involved in managed healthcare for over 21 years which included positions such as an executive in Innovation and Development, Director of Medicines Management, Clinical Executive, Head of Product Development, Chairman of Drugs and Therapeutics Committee, Chairman of Oncology Formulary Committee and Executive of Research and Development. Recently, numerous proposals have been developed to create a paradigm shift in healthcare offerings in South Africa. These offerings include strategic and independent consulting, end-of-life care, centre of excellence, patient-centred care, benefit review, clinical advisory / evidence based medicine, IT system development, new product development, disease management at the point-of-care, etc. Detailed proposals are available on request. Unique models to measure the value of healthcare interventions have been developed using ‘real world data’.
Disease management / health outcomes / wellness
Praneet has been extensively involved with the re-design of disease management programmes with a focus on measuring health outcomes. These programmes were designed to track individual patients over time based on health outcomes principles for the following diseases: asthma, diabetes, osteoporosis, depression, allergy, dyslipidaemia, hypertension, bipolar mood disorder and oncology.
He published the first health outcomes model worldwide for managing epilepsy with phenytoin – part of his PhD. He recently developed unique patient disease management tutorials that empower patients to measure their own clinical outcomes. This system allows individual tracking of patients’ progress. As part of the wellness programme, a proposal on smoking cessation will be provided on request.
Research
​
Praneet has been involved in research for 41 years. He has worked on over 100 research projects that are unique worldwide that contribute to global knowledge. He has supervised postgraduate students in research with particular focus on the pharmacoeconomics of the management of asthma, diabetes and breast cancer.
Our Proposals
All proposals are available on request.
Pharmaceutical Companies
Praneet Valodia has been working in the pharmaceutical field for 41 years. The proposal highlights 27 areas and 40 action items for consideration.
Patient-centricity
This proposal highlights 20 areas for development with 45 action items of how beneficiaries can empower themselves to reduce costs and improve the quality of care. This approach is intended to reduce wastage, improve utilization and quality of care.
Hospitals
Medical Schemes
This proposal focusses on strategic consulting, alternative delivery models, electronic health records (including disease-specific records) that use health intelligence, enhanced hospital discharge services, patient-centricity and empowerment, Centres of Excellence, clinical governance, antibiotic stewardship, health technology assessment, etc.
The proposal focuses on strategic and independent consulting, measuring the value of healthcare interventions (i.e. health outcomes), patient-centricity, thresholds for cost of care, Centre of Excellence (including palliative care), benefit review, clinical advisory / evidence-based medicine, smart technology, curative versus palliative care, primary care, etc.
​
​
Comprehensive Care -Oncology
Smoking Cessation
This programme is also termed a Centre of Excellence (CoE). A CoE is a place where the highest standards are maintained and a place of high achievement. It displays a quality of being outstanding or extremely good. Highly skilled experts are involved in research and innovation to advance the field. A CoE is a team, a shared facility or an entity that provides leadership, best practices, research, support and/or training for a focus area. Peer review will be an essential component of the CoE. The proposal highlights 17 areas that should be part of a CoE. Such a CoE will most importantly measure health outcomes with the ability to track individual patients over time. Such a CoE should be a preferred provider for funders.
Smoking cessation is considered the single most effective primary prevention strategy for reducing the risk of lung cancer deaths in smokers. The aim of this programme is to develop a personalized treatment plan for smokers. Prof Valodia has been actively involved in advising and presenting at conferences on smoking cessation. This programme uniquely incorporates the application of the following: health outcomes research, pharmacology expertise, evidence-based medicine, disease management, data analytics and reporting and innovation.
​
​